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Protocol
AbstrACt
Introduction Quality of life and other key outcomes may 
be improved by optimising hearing and vision function 
in people living with dementia. To date, there is limited 
research assessing the eficacy of interventions aimed 
at improving hearing and vision in people with dementia. 
Here, we outline a protocol to ield test a newly developed 
home-based intervention, designed to optimise sensory 
functioning in people with dementia in three European 
sites. The results of this study will inform the design and 
conduct of a full-scale randomised controlled trial (RCT) in 
ive European sites.
Methods and analysis In this multisite, single arm, open 
label, feasibility study, participants with dementia (n=24) 
will be assessed for hearing and vision impairments 
and be prescribed a hearing aid and/or glasses. Each 
participant will have a study partner (‘dyads’). A subset 
of dyads will receive ‘sensory support’ from a ‘sensory 
support therapist’, comprising home visits over 12 
weeks. The therapist will offer the following intervention: 
adherence support for corrective devices; adaptations 
to the home environment to facilitate sensory function; 
communication training; and referral to community-
based support services. The primary outcomes will be 
process measures assessing the feasibility, tolerability 
and acceptability of: (1) the intervention components; (2) 
the method of implementation of the intervention and 
(3) the study procedures, including outcome assessment 
measures. Quantitative data will be collected at baseline 
and follow-up. Qualitative data using semistructured 
interviews will be collected postintervention and weekly, 
using participant diaries. Finally, we will explore a model 
of cost-effectiveness to apply in the subsequent full-
scale trial. This feasibility study is a necessary step in the 
development of a complex, individualised, psychosocial 
intervention. The data gathered will allow logistical and 
theoretical processes to be reined in preparation for a 
full-scale RCT.
Ethics and dissemination Ethical approval was obtained 
in all three participating countries. Results of the ield 
trial will be submitted for publication in a peer-reviewed 
journal.
IntroduCtIon
In Europe, there are approximately 
10.5 million people living with dementia.1 
Furthermore, over two-thirds of older 
Europeans experience age-acquired sight or 
hearing loss.2 Presbycusis is one of the most 
common age-related conditions3 and the rate 
of self-reported hearing difficulties increases 
in the older adult population with the onset 
of dementia.4 For the general population 
aged 75 years and above, one in four people 
experience sight loss and for those people 
aged 85 years and above this rises to one in 
three people.5 Sight loss in dementia is more 
prevalent than in healthy older adult popu-
lations.6 Despite the prevalence of sensory 
impairment in dementia, hearing and vision 
loss is often not diagnosed and not treated.7 
The comorbidity of sensory impairment 
and dementia has been associated with an 
increased mortality rate in the elderly,8 and 
hearing and vision deficits are independent 
risk factors for increased cognitive impair-
ment, lower quality of life, anxiety and 
depression in people with dementia.9–14 The 
higher prevalence of depression and disori-
entation may lead to isolation from family, 
loss of social activities and hobbies and 
marginalisation within the community, as the 
person is less able to use visual and auditory 
cues to orientate themselves and communi-
cate.15–17 Caregiver burnout is compounded 
strengths and limitations of this study
 Ź This study is limited by being adaptable to the 
pragmatic realities of a multicountry project while 
maintaining scientiic integrity. For example, in terms 
of understanding different health organisations and 
ethics processes, monitoring accurate translation of 
questionnaire scales, permissions and copyright.
 Ź This study is  led by experienced research leaders 
across the ields of psychiatry, psychology, 
optometry and audiology.
 Ź This study has an integrative, iterative approach to 
the research programme; testing the feasibility and 
operational aspects of the sensory intervention aims 
to enable a more robust, subsequent randomised 
controlled trial.
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by communication barriers and a greater dependency of 
self-care for activities of daily living.18
There is a small existing literature regarding the appli-
cation of hearing and vision rehabilitation in older people 
with sensory impairments,19–21 but this does not compre-
hensively extend to people who have concurrent cogni-
tive impairment, particularly dementia.22 Despite this, 
there is some preliminary evidence that sensory remedi-
ation in dementia can be effective in the following ways: 
alleviating personal and social difficulties23; decreasing 
the impact of behavioural and psychological symptoms of 
dementia24; improving cognition with hearing aid use25 26 
and reducing social isolation.27 Nonetheless, to be effec-
tive, treatment should be introduced at an early stage in 
the condition28 and should be tailored to suit the specific 
care needs of the individual.29 For example, optometric 
assessments may need to be adapted for older people 
with dementia to account for the impact of impaired deci-
sion-making and the fluctuation in cognitive ability and 
mental capacity.30
Psychosocial therapies offer a potential solution for 
improving quality of life for people with dementia and 
concurrent sensory impairment. Here, we outline a 
protocol to field test the feasibility and tolerability of a 
newly developed home-based, individualised interven-
tion, with psychosocial aspects, designed to support 
hearing and vision functioning in people with dementia. 
The results of this field trial will inform the design and 
conduct of a full-scale randomised controlled trial (RCT) 
across several European sites evaluating the efficacy of 
this ‘sensory support intervention’ (SSI) on quality of life 
and other outcomes in people with dementia. This study 
is part of a wider programme: the ‘SENSE-Cog project’.
theoretical basis for a new intervention
The new intervention being field trialled here, the 
‘SENSE-Cog SSI’, is based on the premise that improving 
sensory deficits through corrective devices alone may 
not be sufficient to improve outcomes for people with 
dementia. Instead, the SSI aims to offer a period of 
sustained support delivered by a sensory support ther-
apist (SST) to participants, to assist them to achieve 
positive, lasting changes in behaviour, as a result of opti-
mised sensory rectification. This support is as follows: 
continuous training in use of glasses and hearing aids; 
promoting a ‘sensory friendly’ home environment; 
delivering communication techniques and assisting with 
access to community support services. It is anticipated 
these SSI components will lead to a change in behaviour 
by improving uptake of glasses and hearing aids through 
daily wear and second, improving the persons quality 
of life (measured by DemQol and DemQol Proxy),31 
for example, by participating in activities which may 
have been previously hindered or avoided, as a result of 
sensory impairment. Encouraging a change in behaviour 
can be challenging and evidence has shown that many 
attempted behaviour changes may not be sustained, 
unless key underlying elements are addressed.32 In this 
study, the underlying elements are existing attitudes 
and knowledge about participants’ own sensory impair-
ment and towards sensory equipment, contributing to 
subsequent behaviours such as avoiding social situations 
or impaired communication. Consequently, we have 
developed our SSI using an evidenced-based model of 
behavioural change, the COM-B model,33 as the theoret-
ical framework. Each component of the SSI aligns with 
each domain of the COM-B model, as outlined in table 1: 
‘capability’ (C); ‘opportunity’ (O) and ‘motivation’ and 
aims to promote a sustained behavioural change (B) in 
the appropriate usage of sensory equipment and living 
well with dementia and sensory impairment (see table 1).
rEsEArCh quEstIon
overall research question
Is a newly developed, individualised, sensory support 
intervention for people with dementia and concurrent 
sensory impairment suitable for full-scale efficacy testing 
in a subsequent RCT in different European sites?
speciic research questions for the feasibility study
 Ź What is the optimal manner to implement an SSI in 
the participant group?
 Ź What is the acceptability and tolerability of the SSI by 
participants?
 Ź What specific local contextual issues should be consid-
ered in delivering a full trial across multiple different 
EU sites?
 Ź Is it possible to use the health economics data in a cost 
effectiveness model?
MEthods And AnAlysIs
research design
This is a single-arm, open-label field study with no control 
group, to assess the feasibility, acceptability and tolera-
bility of a new sensory support intervention for people 
with dementia (PwD) and concurrent hearing and/or 
vision impairment.
study procedures
We will recruit 24 participant dyads, each comprising a 
PwD and their study partner, across three clinical sites 
(eight dyads per site) in Manchester, UK; Bordeaux, 
France and Nicosia, Cyprus. Following a full hearing 
and vision assessment, each participant will receive a 
hearing aid and/or glasses, if required, alongside either 
basic support of sensory equipment in an ‘abbrevi-
ated’ intervention (components 1 and 2) over three to 
four visits across 3–4 weeks or ‘extended’ support (n=4 
participants in Manchester). The extended intervention 
will be delivered to participants by a research therapist, 
the SST. The research therapist has experience in deliv-
ering supportive interventions to people with long-term 
conditions and will receive additional training in hearing 
and vision rehabilitation. Starkey Hearing Technologies 
will provide an operations manual for the provision of 
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hearing devices and advice on care specific to the device. 
They will also provide training to the SST on the correct 
maintenance and cleaning of the hearing aid. The abbre-
viated version of the intervention will allow testing of the 
‘logistics’ circuit’ for the supply of the corrective devices 
(hearing aids and glasses), the scheduling of the hearing 
and vision assessments, the timing of the baseline and 
end-point outcome evaluations, the operations of the 
recruitment and retention strategy and the tolerability of 
the study protocol and procedures. Additionally, at the 
Manchester site, the extended intervention (components 
3 to 7) will enable us to evaluate each component of the 
intervention and the fidelity of delivery of the interven-
tion by the SST. After each visit, the PwD, study partners 
and the SST will complete a diary to capture experiences, 
acceptance, tolerability and adherence to procedures. A 
subset of participants (n=15) will undertake a semi-struc-
tured interview postintervention to ascertain perceptions 
and experiences of the intervention. The schedule of 
study procedures is outlined in table 2.
study sample34
Participants with dementia: inclusion criteria
To be included in the study, each person with dementia 
must meet the following inclusion criteria:
 Ź Age 60 years or older;
 Ź Has a formal, clinical diagnosis of dementia of the 
following subtypes: Alzheimer’s disease (AD), as 
per National Institute of Neurological and Commu-
nicative Disorders and Stroke and the Alzheimer's 
Disease and Related Disorders Association (NINCDS-
ADRDA) criteria35; vascular dementia (VaD) or mixed 
AD/VaD;
 Ź Montreal Cognitive Assessment (MoCA)35 score of 12 
or above;
 Ź Adult acquired hearing and/or vision impairment;
 Ź Hearing threshold >35 dB HL over 1–3 kHz and/
or vision score of present binocular corrected visual 
acuity of ≤6/9, 5 Snellen metric or +0.2 LogMAR (75 
Early Treatment Diabetic Retinopathy Study (ETDRS) 
Score) and/or visual field of 10–20°;
 Ź Speaks and understands the language of the interven-
tion delivery;
 Ź Is willing to accept sensory support;
 Ź Is living in an ordinary community dwelling 
(including sheltered and very sheltered 
accommodation);
 Ź Has a study partner willing to participate in the study 
(a family member or close friend who is either cores-
ident or in regular contact (at least three times per 
week);
 Ź Has mental capacity sufficient to give informed 
consent to participate.
Participants with dementia: exclusion criteria
If the person with dementia has one or more of the 
following, they will be excluded from participation in the 
study:
 Ź Congenital hearing or vision impairment;
Table 1 The capability, opportunity, motivation—behavioural model and the corresponding components of the sensory 
support intervention leading to anticipated behavioural change
COM-B domain Capability (C) Opportunity (O) Motivation (M)
Meaning The individual’s psychological and 
physical capacity to engage in the 
activity concerned
External factors which impact 
on the individual’s ability 
to ‘live well’ with dementia. 
For this study, we focus on 
living well with dementia and 
sensory impairment
‘Brain processes that energise 
and direct behaviour, as well as 
goals and conscious decision-
making’(33 p4) In dementia, 
these aspects may increasingly 
become impaired, particularly 
with the development of 
apathy58 59
SSI component (c) c1: correct visual/auditory impairment; 
c2: training in correct use of hearing 
aid/glasses; c3: communication 
training; c4a: Home-based functional 
assessment
c5: referral to health and social 
care services; c6: provision 
of supplementary sensory 
devices
c4b: individualised goal setting; 
c7: referral to social/hobby/
interest activities
Glasses and hearing aid correct and regular usage Participation in activities/hobbies/groups previously hindered by sensory 
impairment Attainment of goals previously hindered by sensory impairment Improved communication with spouse and in 
different environments
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Table 2 SENSE-Cog SSI ield trial schedule of events and assessments
Baseline SSI*
Follow-
up
Visit number / / 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Visit week −2 −1 0 1 2 3 4 5 6 7 8 9 10 11 12 13
Allowable visit window:+/−3 days
Identiication X
Information X
Recruitment X
Informed consent X
Screening: HearCheck X
Screening: PEEK Acuity (Worldwide)  X
Screening: visual ield X
Screening: MoCA X
LV-VFQ-20 X A (A) X
HHIE-S X A (A) X
DEM-QOL X A (A) X
DEM-QOL-P X A (A) X
NPI X A (A) X
GSE X A (A) X
EQ-5D-5L X A (A) X
EQ-5D-5L-P X A (A) X
PHQ-15 X A (A) X
SF-12 X A (A) X
SF-12-P X A (A) X
GDS-15 X A (A) X
FCRS X A (A) X
BADLS X A (A) X
RSS X A (A) X
RUD-Lite baseline X
RUD-Lite follow-up A (A) X
Ophthalmological assessment† X
Audiological assessment† X
Glasses itting X (X) (X)
Hearing aid itting‡ X X (X) (X)
SST diary X X X X X X X X X X X X
PwD diary X X X X X X X X X X X X
SP diary X X X X X X X X X X X X
Continued
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Baseline SSI*
Follow-
up
Visit number / / 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Visit week −2 −1 0 1 2 3 4 5 6 7 8 9 10 11 12 13
Sensory devices training X X (X) (X) (X) (X) (X) (X) (X) (X)
Functionality/usability of sensory devices X X X X X X X X X X X X
Communication training X (X) (X) (X) (X) (X) (X) (X) (X) (X)
Goal setting X (X)
Goal review X (X) (X) (X) (X) (X) (X) (X)
Goal outcome X (X) (X) (X) (X) (X)
Referral to clinical/social services X (X) (X) (X) (X) (X) (X) (X)
Provision of supplementary devices X (X) (X) (X) (X) (X) (X)
Develop hobbies, interests X (X) (X) (X) (X) (X)
Semistructured interview A X
Revisit and recap (F2F or phone)§ X X X X X
Key, X on this date; (X)—may take place/follow on, on this date; A—abbreviated intervention participants only; (A)—may take place/follow on at this date for abbreviated intervention participants.
*This details the process for the full intervention. The ‘abbreviated’ intervention will complete at week 3 with follow up assessments and follow-up interviews at week 4/5. The order of the SSI is lexible, depending on 
time to receive sensory equipment and participant’s needs.60
†Ophthalmological and audiological assessments will be conducted based on positive screening results. Not all participants will receive full clinical hearing and vision screening, if not required. Hearing aids and glasses 
are prescribed if deemed necessary by clinical assessment. Not all participants may require both hearing aid and glasses. 
‡There may be a longer duration than 1 week between prescribing a hearing aid and receipt of hearing aid, depending if instant it or moulded it. The SST will undertake SSI visits during this time on weekly basis.
§Revisit and recap: these additional weeks of intervention allow for the SST to revisit and recap any of the previous components in more depth and to work on goal-setting and achievement activities with the person 
with dementia and study partner.
BADLS, Bristol Activities of Daily Living Scale47; DEM-QOL, Dementia Quality of Life31; DEMQOL-P, Dementia Quality of Life Proxy31; EQ-5D-5L-P, EuroQol 5 Dimensions 5 Levels Proxy55; EQ-5D-5L, EuroQol 5 
Dimensions 5 Levels55; F2F, face to face; FCRS, Family Caregiving Role Scale61; GDS-15, Geriatric Depression Scale (15-item)62; GSE, Generalised Self-Eficacy Scale Chen63; HHIE-S, Hearing Handicap Inventory for 
the Elderly Screening Tool34); LV-VFQ-20, Low Vision Visual Functioning Questionnaire—20-item64; MoCA, Montreal Cognitive Assessment36; NPI, Neuropsychiatric Inventory Cummings65; PHQ-15, The Patient Health 
Questionnaire (15 item)60; PwD, person with dementia; RSS, Relationship Satisfaction Scale Burns66; RUD-Lite, Resource Utilisation in Dementia57; SF-12-P, 12-Item Short Form Survey Proxy56;56 SP, study partner; SSI, 
sensory support intervention; SST, Sensory Support Therapist.
Table 2 Continued 
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 Ź Unstable, acute and current psychiatric or physical 
condition severe enough to prevent them from under-
taking the study procedures;
 Ź Has a less common form of dementia (eg, Parkinson's 
disease dementia, dementia with Lewy bodies, fronto-
temporal dementia);
 Ź Is currently participating in any other medication or 
non-medication related trial;
 Ź Has urgent treatment scheduled for hearing or vision 
(eg, cataract operation, treatment for macular degen-
eration needed).
Study partner: inclusion criteria
To be included in the study, the study partner must meet 
the following inclusion criteria:
 Ź Age 18 years or older;
 Ź Speaks and understands language of intervention 
delivery;
 Ź Able to read and write;
 Ź Not employed as a professional carer for the PwD, 
(except Nicosia, which may include professional, 
live-in carers);
 Ź Is a family member or a close friend who is either 
coresident or in regular contact (minimum of three 
times per week).
Study partner: exclusion criteria
If the person with study partner has the following, they 
will be excluded from participation in the study:
 Ź Has an unstable, acute and current psychiatric or 
physical condition severe enough to prevent them 
from participating.
screening methods
Cognition will be screened by administering the MoCA.36 
Hearing will be screened with a simple handheld 
screening device, ‘HearCheck’.37 Vision will be screened 
using the ‘PEEK Acuity App’38 alongside the confronta-
tion visual field test: ‘can you see my hands?’.39
recruitment
Recruitment will occur over a 3-month period, begin-
ning Spring 2017. In all three sites, participants will 
be recruited from local memory clinics and dementia 
research registries. Ethically approved participant infor-
mation sheets (PIS) will be provided to inform potentially 
eligible participants about the study. At least 24 hours will 
be given for the potential participants to read and under-
stand the PIS, prior to being offered a screening appoint-
ment. Informed, written consent will be obtained prior to 
participation and following an assessment of capacity to 
consent to the study.
the intervention
The SSI to be field tested was developed in accordance with 
the UK’s Medical Research Council’s (MRC) guidelines on 
the development and testing of complex interventions.40 
This involved a multistage programme which generated data 
that were synthesised to develop the current version of the 
intervention. Details of the this development programme 
are reported elsewhere41 and involved the following: (1) 
scoping the gaps in understanding, awareness and service 
provision for the hearing and/or vision impairment care 
needs of people with dementia, using a systematic literature 
review42 and an expert reference group; (2) investigating 
the support care needs through a literature search, stake-
holder survey, focus groups, semistructured interviews and 
an expert reference group, leading to a prototype sensory 
support package; (3) refining the prototype through addi-
tional input from stakeholders using focus groups and semi-
structured interviews. Input from lay members (the ‘patient 
and public voice’) is a cornerstone of the work and informed 
the development process at each step.43
Components of the intervention
The complete intervention comprises seven components. 
For this field trial, an abbreviated version of the intervention 
(the abbreviated intervention comprising only components 
1 to 2) will be administered in the study sites in Nicosia and 
Bordeaux. In the Manchester site, the full intervention (the 
extended) will be administered.
Abbreviated intervention
Following screening, participants at all three sites will be 
administered the following intervention components:
Component 1: identify and correct any vision or hearing 
impairment
Vision and hearing assessments will be undertaken by an 
audiologist, optometrist or ophthalmologist, according to 
standardised procedures (see table 3).
Should medical management of cataracts or macular 
degeneration be necessary following this visual assess-
ment, participants will be deemed ineligible for the 
study and referred for medical or surgical management 
as per standard care. Essilor International44 will provide 
the lenses for the study. Starkey Hearing Technologies45 
(based in Stockport, UK) will provide the hearing aids. 
These will be the ‘behind the ear’ fitting Muse Mini BTE 
i2400.
Component 2: continuous training in the correct use of sensory 
devices
The SST will work with participants to ensure adherence 
and correct usage of the prescribed hearing aids and 
glasses. For example, advice will be given on cleaning 
and storing devices correctly and changing batteries as 
required (based on a checklist provided by Essilor Limited 
and Starkey Hearing Technologies).
Extended intervention
Following components 1 and 2, each participant in the 
Manchester site will be contacted by the research thera-
pist, the SST, to undertake the remaining components of 
the intervention over a 12-week period, with a maximum 
of 12 weekly, one 2-hour sessions in the participants’ 
home (see table 2). Each intervention step will be tailored 
to meet the participant’s individual needs, which will be 
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considered from multiple perspectives (environment, 
existing knowledge and skills and access to services). The 
remaining five components (components 3 to 7) may be 
delivered in a flexible order.
Component 3: communication training
Communication difficulties are a barrier to living well 
with dementia and sensory impairment.46 Based on 
findings from our focus group with occupational ther-
apists from across Europe (step 2 of our development 
programme), communication difficulties between a 
person with dementia and sensory impairment and 
their spouse was  a prominent theme. The SST will work 
with dyads on improving communication, using adapted, 
evidence-based materials.
Component 4: home-based functional assessment and goal setting
During baseline assessments, the PwD will complete 
the Bristol Activities of Daily Living Scale,47 a home-
based functional assessment of activities of daily living. 
Combined with the results of the hearing and/or vision 
assessment, this will form the basis for setting person-
alised goals by the participant and their study partner, 
supported by the SST. Goal setting is a highly successful 
strategy for use in this population.48 Goals will be revisited 
by the SST on a weekly basis. The Bangor Goal Setting 
Inventory, which reviews goal attainment at 25%, 50%, 
75% and 100% increments,49 50 will be the tool used by 
the SST to assist the participant dyad with goal setting and 
monitoring achievement of goals.
Component 5: referral to health and social services
Based on the functional assessment and goals set in 
component 6, the SST may refer participants to health 
or social care services in the community. This may 
include psychological services, geriatric psychiatry 
services, falls’ clinics or other services, as indicated by 
the assessments and goal-setting exercises. This will 
be particularly important for participants who may be 
socially isolated and not in contact with supporting 
agencies.
Component 6: provision of supplementary sensory devices to 
enhance the home environment
Participants with visual impairment will be offered a 
lamp (The Daylight CompanyTwist Portable Lamp in 
White D33700) to assist with low vision in the home 
setting. Glasses’ straps and hearing aid clips will be 
provided, if required. Participants will be signposted to 
beneficial devices to support vision and hearing func-
tion in the home, which may correspond with their goal 
setting.
Component 7: fostering social inclusion through hobbies/interests/
social groups
People with dementia and sensory impairment may 
become isolated from family and the wider community.51 
Thus, it is important to link dyads to community groups 
and resources, based on their hobbies and interests. 
Information about support for hobbies and interests will 
be sourced from local charities and healthcare providers.
Component 8: recap and revisit
The remaining weeks allow the SST to revisit and recap 
previous components, based on the participant’s indi-
vidual needs and goal-attainment.
outcome measures
Primary outcome measures
A set of process measures will be undertaken to assess 
the primary outcomes of the study: are the interven-
tion components, method of implementation and study 
processes are feasible, acceptable and tolerated? This 
includes an assessment of the following: recruitment; 
retention; screening procedure; inclusion/exclusion 
criteria; assessment of impairment; the role of support 
offered by the SST; delivery and fitting of devices and the 
functional assessment procedure. We will also include 
measures of behavioural change, as per the COM-B 
approach (capability, opportunity and motivation) 
regarding the use of hearing aids and glasses, captured 
by the diaries and semistructured interviews (see table 4).
Table 3 Audiological and ophthalmological examination procedures
Audiology examination Ophthalmological examination
Medical and social history Current optical correction
Otoscope Habitual vision/habitual Visual Acuity (both LogMAR and Snellen equivalent)
Ambient noise evaluation Medical and vision history
Pure tone audiometry Intraocular pressures
Uncomfortable loudness levels examination Ocular motor balance assessment
Glasgow Hearing Aid Beneit Proile67 Ocular health assessment using direct ophthalmoscopy
Fundus
Subjective prescription indings
Objective prescription indings using retinoscopy
Visual ield testing
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Secondary outcome measures
The secondary outcome is to gain an initial impression 
of treatment efficacy and ascertain the utility of different 
ratings scales. We will examine preintervention (base-
line) and postintervention (follow-up) measures using a 
battery of rating scales of the following dementia-related 
outcomes, completed by the PwD and study partner: 
quality of life; behaviour/mood; general mental well-
being; functional ability; mental health; social connect-
edness; burden and stress due to the caregiver role and 
caregiver/patient relationship. It is important to include 
economic evaluation during field testing to ascertain 
utility for the subsequent RCT52 and we will assess the use 
of the quality of life and healthcare resource instruments. 
For full details of scales corresponding to field study 
outcome, see table 5.
data analysis
Qualitative analysis
The qualitative analyses of the semistructured interviews 
and diaries will highlight aspects of perceived efficacy. 
Data from the diaries and verbatim data from the inter-
views will be analysed using summative content analysis.53 
The findings will be analysed into codes and descriptive 
evidence to support the coding framework. A subsection of 
interview sessions (n=15) will be audiotaped, transcribed 
verbatim and analysed using MaxQda qualitative soft-
ware54 by colleagues at University of Freiburg, Germany. 
The diary material will be analysed by the University of 
Manchester. Based on summative content analysis, we will 
formulate criterion from the theoretical background and 
the research question. This criterion will be as follows: 
the perception of the intervention material; adherence 
Table 4 SENSE-Cog sensory support intervention ield study primary outcomes measures and methods to capture outcomes
Field study outcome Method to capture outcome
PwD effort In-house rating scale in PwD and SP diaries; semistructured interview with both 
dyad membersPwD fatigue
PwD motivation
PwD engagement
PwD understanding
Frequency/duration of SSI sessions SST diary
SSI feasibility Completion rates/missing data at baseline and follow-up
Is SSI delivered as intended? SST diary checklist after each visit
Is SSI received as intended? Records of contact between SST and recipient. This will include information 
on: number and duration of contact, sessions; method; referrals and protocol 
deviations.
PwD and SP will have their knowledge of the SSI components checked by the 
SST
Is SSI enacted as intended? SST, PwD, SP diaries; semistructured interview
Reach Proportion of referred patients who enter the study
Recruitment Number of patients approached versus number recruited
Retention Number of participants withdrawing and reasons
Screening Number of patients screened ‘suitable’ versus ‘unsuitable’
Inclusion/exclusion criteria Feedback from CRN/other recruiters about ease of screening criteria
Assessment of impairment and corrective 
device delivery and itting
SST, PwD, SP diaries; feedback from research team and industry partners
Functional assessments SST, PwD, SP diaries; analysis of frequency of missing data
‘Logistics circuit’ of hearing/
vision assessments and devices
SST, PwD, SP diaries; feedback from research team and industry partners
SST training SST diary will identify areas of training for the role
SST visits SST, PwD, SP diaries; semistructured interview
Glasses usage
Hearing aid usage
Receptivity to sensory equipment
Helpfulness of SSI
Motivation to continue with SSI activities
CRN, Clinical Research Network; PwD, people with dementia; SP, study partner; SSI, sensory support intervention; SST, sensory support 
therapist. 
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to the glasses; hearing aids and sensory support, docu-
mented in terms of behavioural change. We will deduce 
the categories in an iterative manner, based on data from 
the semistructured interviews and diaries. Within a feed-
back loop, the identified categories will be revised and 
refined in to the main themes and checked against the 
data for reliability.
Quantitative analysis
For this feasibility study, we did not perform a formal 
power calculation. Data will be entered into the Statis-
tical Package for the Social Sciences V.20.0.0.2 (SPSS) 
and recoded so all items have a consistent valance. Any 
missing data will be recorded, along with any protocol 
violations. To explore participants’ impression of change 
across various outcome parameters (eg, quality of life, 
cognition, behaviour, social connectedness, mental well-
being, study partner indices), we will examine the differ-
ence (ie, change) between baseline (preintervention) 
and follow-up (postintervention) subjective rating scales 
of ‘perceived efficacy’ to explore the feasibility, toler-
ability and face validity of the measures for the subse-
quent RCT. The distributions of the secondary outcome 
measures, both preintervention and postintervention, 
will be summarised using appropriate measures of central 
tendency (mean or median) and variability (SD or IQR). 
Due to the small sample, we will use a large p value, 0.2, as 
an indication of effect only. The score distributions, both 
preintervention and postintervention, will be examined 
for degree of variability and ceiling and floor effects.
Economic analysis
We will summarise the statistics of EuroQoL 5 Dimen-
sions (EQ-5D),55 12-Item Short Form Survey (SF-12)56 and 
Resource Utilisation in Dementia (RUD)-Lite.57 EQ-5D55 
and EQ-5D Proxy55 version will allow health utility data to 
estimate quality-adjusted life years (QALYs). Costs will be 
calculated based on the number of healthcare resources 
used, collected using RUD-Lite and the reference costs 
estimated from published reports, for example, Personal 
Social Services Research Unit unit costs, administrative 
datasets and/or experts’ opinion. We will conduct explor-
atory modelling work using preintervention and postinter-
vention health economics data to ensure it is possible to 
use these data in a cost-effectiveness model. SF-12-based 
and Dementia Quality of Life-derived health utility data 
will be implemented as alternative ways to calculate QALYs.
Ethics and dissemination
The study has received favourable ethical approval 
for Manchester on 30th September 2016 from the 
NW Preston REC IRAS ID 212501, REC reference 16/
NW/0685 and the Health Research Authority on 29th 
November 2016. For Nicosia, the study was reviewed by 
the Cyprus National Bioethics Committee on the 27th 
September 2016 and bioethical approval was granted. For 
Bordeaux the ethical opinion from the Comité de Protec-
tion des Personnes Sud-ouest et Outremer III was given 
on 25th May 2016.
Manuscripts with the results of this field trial will 
be submitted for publication in peer-reviewed journals. 
We will post results on the SENSE-Cog website (www. sense 
(www. sense- cog. eu/) and on the SENSE-Cog Twitter 
account (@sense_cog). Feedback will be sent to the RCT 
Trial Development Team and disseminated at public 
engagement events.
dIsCussIon
This field trial is the next logical step in a multipart process, 
developing a new, complex intervention. The field trial was 
Table 5 SENSE-Cog SSI ield study secondary outcomes measures and methods to capture outcomes
Tool to capture outcome
PwD outcome
  Quality of life Dementia Quality of Life31; EuroQol 5 Dimensions 5 Levels55; 12-Item Short Form Survey56
  Cognition Neuropsychiatric Inventory65
  General mental well-being Generalised Self-Eficacy Scale63
  Function Bristol Activities of Daily Living Scale47
  Cognition Montreal Cognitive Assessment36
SP outcome
  Quality of Life Dementia Quality of Life Proxy31; EuroQol 5 Dimensions 5 Levels Proxy55; 12-Item Short Form 
Survey Proxy56
  Mental health Geriatric Depression Scale 1562
  Burden and stress Family Caregiving Role Scale61
  Healthcare resource use Resource Utilisation in Dementia Lite57
PwD and SP Outcome
  Relationship Relationship Satisfaction Scale66
  Initial SSI eficacy Dementia Quality of Life31 and Dementia Quality of Life Proxy31
PwD, person with dementia; SP, study partner; SSI, sensory support intervention
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designed to refine and test the feasibility, tolerability and 
acceptability of a draft intervention to support hearing and 
vision functioning in PwD living at home across Europe. 
Data from this field trial will highlight weaknesses and 
strengths in the components and implementation of the 
intervention, as well as the study procedures and conduct 
in preparation for a five-site, full-scale RCT beginning 
Autumn 2017. This field trial will also evaluate the efficacy 
of a new job role designed specifically for the SENSE-Cog 
research, the SST; allow refinement of the SST training, SST 
job description and step-by-step user manuals across sites 
prior to the RCT. While the RCT will test the efficacy of the 
SSI and impact on quality of life for people with dementia 
and study partners, trialling of these operational aspects ‘in 
the field’ prior to the RCT is imperative to ensure these 
can be optimally implemented in a larger scale, complex, 
multisite, cross-disciplinary study.
The outcome of the subsequent RCT aims to expound 
the benefits of a domiciliary approach for hearing and 
vision assessments and sustained support for people with 
dementia. This sensory support package is derived from 
existing local resources, driven by person-centred goals 
and could potentially lessen the economic impact on EU 
clinical services, by offering a home-based, individual-
ised alternative to a pharmacological model of care for 
dementia and sensory loss.
study timeline
The overall programme started on 1st January 2016. 
The Expert Reference was held in Athens, Greece 
in April 2016. Applications for ethical approval were 
submitted and favourable approval received in August 
and September 2016. This study will begin recruiting in 
Spring 2017 and will be completed by September 2017. 
The RCT to follow this development programme is sched-
uled to begin in November 2017.
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